{"id":127285,"name":"JAZZ PHARMACEUTICALS","slug":"jazz-pharmaceuticals","state":"CA","country":"United States of America","description":"&#226;€‹Biopharmaceutical company.","totalSpending":1600000,"filings":30,"yearlySpending":[{"year":2019,"income":240000},{"year":2020,"income":240000},{"year":2021,"income":240000},{"year":2022,"income":240000},{"year":2023,"income":240000},{"year":2024,"income":200000},{"year":2025,"income":200000}],"issues":[{"code":"HCR","display":"Health Issues"},{"code":"BUD","display":"Budget/Appropriations"},{"code":"MED","display":"Medical/Disease Research/Clinical Labs"}],"firms":["TIBER CREEK GROUP"],"lobbyists":["SEAN RICHARDSON","JONATHON JONES","JOHN GONZALEZ","ANDREW MCKECHNIE","TIMOTHY MOLINO","JAMES HEIMBACH","MATTHEW LEFFINGWELL","EMILY KIRLIN"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE"],"sampleDescriptions":["Issues related to the Food and Drug Administration and appropriations.","Issues related to the Food and Drug Administration and appropriations.","Issues related to the Food and Drug Administration and appropriations.","Issues related to the FDA and the STATES Act (S. 3032)","Issues related to the FDA and the STATES Act (S. 3032)"]}